OSE OSE Immunotherapeutics SA

OSE Immunotherapeutics met à jour l’information sur les procédures en cours

OSE Immunotherapeutics met à jour l’information sur les procédures en cours

OSE Immunotherapeutics provides an update on ongoing proceedings



NANTES, France, July 2, 2025, 8 AM –
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that following the hearing on June 24th, 2025, the President of the Nantes Commercial Court rejected, pursuant to an order dated July 1, 2025, the motions brought by the group of shareholders acting in concert, seeking the retraction of the order of June 10, 2025, authorizing the adjournment of the OSE’s annual general meeting1.

Furthermore, as communicated on June 20, 20252, OSE Immunotherapeutics introduced the accelerated procedure, so called “on a set day” (à bref délai), against the same group of shareholders, for a hearing scheduled for September 8, 2025. As a reminder, this action concerns the regularity of the declaration of the concerted action, with the aim of ensuring compliance with the principles of transparency governing shareholder democracy ahead of the next annual general meeting.

Subject to the evolution of these legal proceedings, OSE Immunotherapeutics confirms that it currently plans to hold the annual shareholders’ meeting on September 30th, 2025.

ABOUT OSE IMMUNOTHERAPEUTICS

OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: -immuno.com. Click and follow us on LinkedIn.

 Follow us on Linkedln.



Contacts

Fiona Olivier





Sylvie Détry





France Contact Media:

FP2COM

Florence Portejoie



+33 6 07 768 283
U.S. Contact Media:

RooneyPartners LLC

Kate Barrette







Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.


1

2

Attachment



EN
02/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OSE Immunotherapeutics SA

 PRESS RELEASE

Informations relatives au nombre total de droits de vote et d’actions ...

Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 2 juillet 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), société intégrée de biotechnologie qui développe des immunothérapies innovantes, en direct ou via des partenariats, pour l’activation et la régulation immunitaire en immuno-oncologie et en immuno-inflammation, i...

 PRESS RELEASE

OSE Immunotherapeutics met à jour l’information sur les procédures en ...

OSE Immunotherapeutics met à jour l’information sur les procédures en cours OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that following the hearing on June 24th, 2025, the President of the Nantes Commercial Court rejected, pursuant to an order dated July 1, 2025, the motions brought by the group of shareholders acting in concert, seeking the retraction of the order of June 10, 2025, authorizing the adjournment of the OSE’s annual general meeting1. Furthermore, as c...

 PRESS RELEASE

OSE Immunotherapeutics met à jour l’information sur les procédures en ...

OSE Immunotherapeutics met à jour l’information sur les procédures en cours OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 2 juillet 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience du mardi 24 juin 2025, le Président du Tribunal de Commerce de Nantes a rejeté, par ordonnance en date du 1er juillet 2025, les demandes formées par le groupe d’actionnaires concertistes visant à la rétractation de l’ordonnance du 10 juin 2025 ayant autorisé l’ajournement de l’assemblée générale annuell...

 PRESS RELEASE

OSE Immunotherapeutics Publishes Letter to Shareholders

OSE Immunotherapeutics Publishes Letter to Shareholders OSE Immunotherapeutics Publishes Letter to Shareholders NANTES, France, June 30, 2025, 6:00 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces the publication of its inaugural Letter to Shareholders. The Company’s CEO and Board of Directors wish to share with shareholders the key achievements of recent months, the foundations of its growth strategy and perspectives for the future. The Letter to Shareholders is available on the Company's website: . ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is...

 PRESS RELEASE

OSE Immunotherapeutics publie une Lettre aux Actionnaires

OSE Immunotherapeutics publie une Lettre aux Actionnaires OSE Immunotherapeutics publie une Lettre aux Actionnaires NANTES, France, 30 juin 2025, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), annonce la publication de sa première Lettre aux Actionnaires. Le Directeur général et le Conseil d’administration de la Société souhaitent partager avec les actionnaires les réalisations clés des derniers mois, les perspectives à venir et les fondements de sa stratégie de croissance. La Lettre aux Actionnaires est disponible sur le site internet de la Société : . À PRO...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch